IFNA1 and systemic lupus erythematosus: These efforts, combined with the unprecedented SLE clinical trial activity in the past two decades, have culminated in the approval of the first agent targeting the IFN pathway for the treatment of patients with SLE [104], highlighting that type I interferon is a viable therapeutic target that reduces disease activity in patients with SLE and other autoimmune diseases.